Wells Fargo’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-8,592
| Closed | -$346K | – | 7289 |
|
|
2026
Q1 | $346K | Sell |
8,592
-95,223
| -92% | -$2.05M | ﹤0.01% | 4353 |
|
|
2025
Q4 | $2.61M | Buy |
103,815
+101,352
| +4,115% | +$2.38M | ﹤0.01% | 3227 |
|
|
2025
Q3 | $55.7K | Sell |
2,463
-1,041,192
| -100% | -$24.3M | ﹤0.01% | 5521 |
|
|
2025
Q2 | $18.1M | Buy |
1,043,655
+1,039,031
| +22,470% | +$19.2M | ﹤0.01% | 1482 |
|
|
2025
Q1 | $101K | Sell |
4,624
-992
| -18% | -$27.4K | ﹤0.01% | 5100 |
|
|
2024
Q4 | $179K | Sell |
5,616
-133,752
| -96% | -$4.02M | ﹤0.01% | 4861 |
|
|
2024
Q3 | $4.02M | Sell |
139,368
-20,860
| -13% | -$773K | ﹤0.01% | 2526 |
|
|
2024
Q2 | $6.15M | Buy |
160,228
+15,193
| +10% | +$688K | ﹤0.01% | 2106 |
|
|
2024
Q1 | $8.53M | Buy |
145,035
+12,468
| +9% | +$795K | ﹤0.01% | 1873 |
|
|
2023
Q4 | $7.94M | Sell |
132,567
-23,140
| -15% | -$1.17M | ﹤0.01% | 1872 |
|
|
2023
Q3 | $5.92M | Buy |
155,707
+63,512
| +69% | +$2.79M | ﹤0.01% | 1989 |
|
|
2023
Q2 | $8.4M | Sell |
92,195
-13,423
| -13% | -$1.16M | ﹤0.01% | 1732 |
|
|
2023
Q1 | $6.97M | Buy |
105,618
+88,673
| +523% | +$5.12M | ﹤0.01% | 1859 |
|
|
2022
Q4 | $876K | Sell |
16,945
-2,653
| -14% | -$141K | ﹤0.01% | 3324 |
|
|
2022
Q3 | $1.34M | Buy |
19,598
+3,796
| +24% | +$225K | ﹤0.01% | 3039 |
|
|
2022
Q2 | $714K | Sell |
15,802
-25,617
| -62% | -$1.17M | ﹤0.01% | 3515 |
|
|
2022
Q1 | $2.1M | Sell |
41,419
-22,506
| -35% | -$994K | ﹤0.01% | 3243 |
|
|
2021
Q4 | $3.02M | Buy |
63,925
+13,336
| +26% | +$525K | ﹤0.01% | 3086 |
|
|
2021
Q3 | $1.67M | Buy |
50,589
+14,390
| +40% | +$809K | ﹤0.01% | 3819 |
|
|
2021
Q2 | $2.29M | Buy |
36,199
+26,162
| +261% | +$1.35M | ﹤0.01% | 3567 |
|
|
2021
Q1 | $430K | Sell |
10,037
-38,386
| -79% | -$1.82M | ﹤0.01% | 4766 |
|
|
2020
Q4 | $2.77M | Buy |
48,423
+21,959
| +83% | +$929K | ﹤0.01% | 3261 |
|
|
2020
Q3 | $799K | Sell |
26,464
-14,136
| -35% | -$422K | ﹤0.01% | 4025 |
|
|
2020
Q2 | $1.33M | Buy |
40,600
+9,828
| +32% | +$316K | ﹤0.01% | 3590 |
|
|
2020
Q1 | $825K | Sell |
30,772
-27,773
| -47% | -$986K | ﹤0.01% | 3669 |
|
|
2019
Q4 | $1.79M | Buy |
58,545
+13,067
| +29% | +$362K | ﹤0.01% | 3426 |
|
|
2019
Q3 | $1.09M | Buy |
45,478
+1,480
| +3% | +$40.7K | ﹤0.01% | 3772 |
|
|
2019
Q2 | $1.11M | Buy |
43,998
+20,272
| +85% | +$412K | ﹤0.01% | 3798 |
|
|
2019
Q1 | $463K | Sell |
23,726
-1,802
| -7% | -$28.3K | ﹤0.01% | 4384 |
|
|
2018
Q4 | $337K | Buy |
25,528
+7,617
| +43% | +$117K | ﹤0.01% | 4596 |
|
|
2018
Q3 | $318K | Buy |
17,911
+1,088
| +6% | +$20.1K | ﹤0.01% | 4746 |
|
|
2018
Q2 | $370K | Buy |
16,823
+10,674
| +174% | +$245K | ﹤0.01% | 4672 |
|
|
2018
Q1 | $136K | Buy |
6,149
+4,553
| +285% | +$89.5K | ﹤0.01% | 5174 |
|
|
2017
Q4 | $35K | Buy |
+1,596
| New | +$23.5K | ﹤0.01% | 5645 |
|
Other funds holding APLS
Wells Fargo's APLS Position: Q2 2026 in Review
Wells Fargo sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 8,592 shares — an estimated $346K sold.
Wells Fargo first reported a position in APLS in Q4 2017 and held it in 34 quarters. The position peaked at $18.1M in Q2 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Wells Fargo reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Wells Fargo sold 8,592 Apellis Pharmaceuticals shares in Q2 2026, an estimated $346K.
- Wells Fargo first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 34 quarters.
- Wells Fargo's Apellis Pharmaceuticals position peaked at $18.1M in Q2 2025.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.